FDA Approves STARJEMZA: A New Chapter in Biosimilar Therapy Bio-Thera and Hikma Pharmaceuticals celebrate FDA approval for STARJEMZA, a biosimilar targeting inflammation. This marks a major step in patient access to advanced therapies.

FDA Approves STARJEMZA: A New Chapter in Biosimilar Therapy #China #Guangzhou #Bio-Thera_Solutions #Hikma_Pharmaceuticals #STARJEMZA

FDA Approves STARJEMZA® Biosimilar by Bio-Thera Solutions and Hikma Pharmaceuticals Bio-Thera Solutions and Hikma Pharmaceuticals announce the FDA's approval of STARJEMZA®, a new biosimilar referencing STELARA®, expanding treatment options for patients.

FDA Approves STARJEMZA® Biosimilar by Bio-Thera Solutions and Hikma Pharmaceuticals #USA #Bio-Thera #Hikma_Pharmaceuticals #STARJEMZA #Guangzhou,_China_and_London